Pedro leads the UNITY Biology Team focused on the identification, validation and targeting of novel pathways to selectively eliminate senescent cells and treat age-related diseases. Prior to joining UNITY, Pedro spent 14 years at Amgen, Inc. where he led Discovery and Pharmacology Research programs focused on Oncolytic Viruses (Imlygic™, Melanoma), IGF-1R (ganitumab, Phase 3, Pancreatic Cancer), T790M EGFR, mutant braf, UPR (Development Candidates), and JAK2, AXL (Proof of concept). In these leadership roles, Pedro acquired experience in interrogating novel biology, validating targets, developing clinical candidates, and translating biology into clinical development strategies. During his last 3 years at Amgen, Pedro served as Executive Director of Discovery Research where he led a team of 30+ Scientists and formed part of the Immuno-Oncology Research Senior Leadership Team that progressed more than 10 Development Candidates into Clinical Development. Pedro holds a B.S. in Molecular Biology from the Florida Institute of Technology and a Ph.D. in Cancer Biology from the University of Texas, M.D. Anderson Cancer Center. He was awarded Lois Pope Fellowships for post-doctoral work in Neuroscience at the Miami Project to Cure Paralysis, where he studied tyrosine phosphatases in axon growth and guidance. Pedro has a long track-record of productive collaborations with leading academic groups including one in aging with Nir Barzilai, M.D. and Derek Huffman, Ph.D. from Albert Einstein School of Medicine. Pedro has authored more than 30 peer-reviewed manuscripts and 40+ scientific abstracts. He has been an invited speaker in multiple national and international conferences and holds patents describing novel ways to treat disease.